At Sonnet BioTherapeutics, our primary mission is to pioneer the next generation of oncology-focused immune therapeutics for patients and clinicians. Leveraging our proprietary F_HAB technology platform, Sonnet is exploring novel single and bispecific immunomodulatory cytokine therapeutic candidates.

For more information on our clinical trials, please visit the following pages:

SB101: SON-1010 Dose Escalation in Patients with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT05352750

SB102: Study of SON-1010 (IL12-FHAB) in Healthy Adults
https://clinicaltrials.gov/ct2/show/NCT05408572

SB211: SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)
https://clinicaltrials.gov/ct2/show/NCT05435742

SB221: Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
https://clinicaltrials.gov/study/NCT05756907?term=NCT05756907&rank=1